- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04539392
Vurdering av seksualiteten til det infertile paret (INFEXO)
Vurdering av seksualiteten til det infertile paret: Prospektiv kohortstudie
The study hypothesis is that infertile couples experience an impact of their sexuality impacted during the diagnostic process carried out as part of the medically assisted procreation assessment, and also by the announcement of the possible cause of the couple's infertility. It is also conceivable that a disorder of the couple's sexuality forms the origin of, or is a contributor to, infertility.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
-
Nîmes, Frankrike
- CHU de Nimes
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
80 heterosexual infertile couples (according to the WHO definition) followed at the Nîmes University Hospital in the Urology / Gynecology departments.
Beskrivelse
Inclusion Criteria:
- Couple in which each of the two partners has signed the consent form which is presented separately and independently of their partner.
- The patient must be a member or beneficiary of a health insurance plan
- Heterosexual infertile couple (according to the WHO definition) monitored at the Nîmes University Hospital in the urology / gynecology departments.
Adult patient (≥18 years old) and under 43 years old for women, 60 years old for men
Exclusion Criteria:
- The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
- One member of the couple refuses to sign the consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Patient without good level of written and spoken French
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Ufruktbart par
|
Panel of questionnaires assessing sexuality, relationship satisfaction, and body image |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sexuality of the female of the couple
Tidsramme: 2 weeks after inclusion (start of MAP)
|
Female sexual function index: The total score is between 2 and 36 with sexual dysfunction indicated for scores below 26.55 |
2 weeks after inclusion (start of MAP)
|
|
Sexuality of the female of the couple
Tidsramme: 1 month after ovarian ponction (end of MAP)
|
Female sexual function index: The total score is between 2 and 36 with sexual dysfunction indicated for scores below 26.55 |
1 month after ovarian ponction (end of MAP)
|
|
Sexuality of the male of the couple
Tidsramme: 2 weeks after inclusion (start of MAP)
|
Male Sexual Health Questionnaire |
2 weeks after inclusion (start of MAP)
|
|
Sexuality of the male of the couple
Tidsramme: 1 month after ovarian ponction (end of MAP)
|
Male Sexual Health Questionnaire |
1 month after ovarian ponction (end of MAP)
|
|
Ejactulation of the male of the couple
Tidsramme: 2 weeks after inclusion (start of MAP)
|
Premature Ejaculation Profile |
2 weeks after inclusion (start of MAP)
|
|
Ejactulation of the male of the couple
Tidsramme: 1 month after ovarian ponction (end of MAP)
|
Premature Ejaculation Profile |
1 month after ovarian ponction (end of MAP)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sexuality of the female of the couple
Tidsramme: 1 month after ovarian ponction (end of MAP)
|
Female sexual function index: The total score is between 2 and 36 with sexual dysfunction indicated for scores below 26.55 |
1 month after ovarian ponction (end of MAP)
|
|
Sexuality of the male of the couple
Tidsramme: 1 month after ovarian ponction (end of MAP)
|
Male Sexual Health Questionnaire |
1 month after ovarian ponction (end of MAP)
|
|
Body satisfaction and global self-perception of both members of the couple
Tidsramme: 2 weeks after inclusion (start of MAP)
|
Questionnaire de satisfaction corporelle et de perception globale de soi (QSCPGS): total score ranges from -100 to +100. |
2 weeks after inclusion (start of MAP)
|
|
Body satisfaction and global self-perception of both members of the couple
Tidsramme: 1 month after ovarian ponction (end of MAP)
|
Questionnaire de satisfaction corporelle et de perception globale de soi (QSCPGS): total score ranges from -100 to +100. |
1 month after ovarian ponction (end of MAP)
|
|
Relationship satisfaction of both members of the couple
Tidsramme: 2 weeks after inclusion (start of MAP)
|
Dyadic Adjustment Scale-16 Distress if score less than 92 and without distress if the score is higher than 107 |
2 weeks after inclusion (start of MAP)
|
|
Relationship satisfaction of both members of the couple
Tidsramme: 1 month after ovarian ponction (end of MAP)
|
Dyadic Adjustment Scale-16 Distress if score less than 92 and without distress if the score is higher than 107 |
1 month after ovarian ponction (end of MAP)
|
|
Self-esteem of both members of the couple
Tidsramme: 2 weeks after inclusion (start of MAP)
|
Rosenberg self-esteem scale: The score is between 10 and 40. A score below 25 indicates very low self-esteem. A score between 25 and 31 indicates low self-esteem. A score between 31 and 34 indicates average self-esteem. A score between 34 and 39 indicates strong self-esteem. A score above 39 indicates very high self-esteem. |
2 weeks after inclusion (start of MAP)
|
|
Self-esteem of both members of the couple
Tidsramme: 1 month after ovarian ponction (end of MAP)
|
Rosenberg self-esteem scale: The score is between 10 and 40. A score below 25 indicates very low self-esteem. A score between 25 and 31 indicates low self-esteem. A score between 31 and 34 indicates average self-esteem. A score between 34 and 39 indicates strong self-esteem. A score above 39 indicates very high self-esteem. |
1 month after ovarian ponction (end of MAP)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Stéphanie Huberlant, CHU Nimes
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NIMAO/2019-2/SH-01
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .